Oncogenic Ras/Src cooperativity in pancreatic neoplasia

Oncogene

Volumn 30, Issue 18, 2011, Pages 2123-2134

  Shields, D J ^a   Murphy, E A ^a   Desgrosellier, J S ^a   Mielgo, A ^a   Lau, S K M ^a   Barnes, L A ^a   Lesperance, J ^a   Huang, M ^a   Schmedt, C ^b   Tarin, D ^a   Lowy, A M ^a   Cheresh, D A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

Author keywords

oncogenic cooperativity; pancreatic cancer; Ras; Src

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; GENOMIC INSTABILITY; INVASIVE CARCINOMA; MOUSE; NONHUMAN; ONCOGENE K RAS; ONCOGENE RAS; ONCOGENE SRC; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; GENOMIC INSTABILITY; HUMANS; MICE; ONCOGENES; PANCREATIC NEOPLASMS; RAS PROTEINS; SRC-FAMILY KINASES;

EID: 79955578065     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.589     Document Type: Article

References (51)

1. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J et al. (2003). Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112-3126. (Pubitemid 38040774)
2. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-554.
3. Bardeesy N, Cheng KH, Berger JH, Chu GC, Pahler J, Olson P et al. (2006). Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20: 3130-3146. (Pubitemid 44790628)
4. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. (1991). Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 163: 111-116.
5. Billadeau DD, Chatterjee S, Bramati P, Sreekumar R, Shah V, Hedin K et al. (2006). Characterization of the CXCR4 signaling in pancreatic cancer cells. Int J Gastrointest Cancer 37: 110-119. (Pubitemid 351642211)
6. Bromann PA, Korkaya H, Courtneidge SA. (2004). The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23: 7957-7968. (Pubitemid 39468854)
7. Broome MA, Courtneidge SA. (2000). No requirement for src family kinases for PDGF signaling in fibroblasts expressing SV40 large T antigen. Oncogene 19: 2867-2869. (Pubitemid 30386423)
8. Desgrosellier JS, Barnes LA, Shields DJ, Huang M, Lau SK, Prevost N et al. (2009). An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. Nat Med 15: 1163-1169.
9. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. (1999). Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 4: 915-924. (Pubitemid 30054898)
10. Fanidi A, Harrington EA, Evan GI. (1992). Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359: 554-556.
11. Fenech M. (2000). The in vitro micronucleus technique. Mutat Res 455: 81-95.
12. Grimm J, Potthast A, Wunder A, Moore A. (2003). Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer. Int J Cancer 106: 806-811. (Pubitemid 36993405)
13. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ, Lemoine NR. (1990). The c-erb B-2 proto-oncogene in human pancreatic cancer. J Pathol 161: 195-200. (Pubitemid 20228477)
14. Hernandez-Munoz I, Skoudy A, Real FX, Navarro P. (2008). Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 8: 462-469.
15. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20: 1218-1249. (Pubitemid 43727584)
16. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437-450. (Pubitemid 38050041)
17. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH et al. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7: 469-483. (Pubitemid 40719130)
18. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV et al. (2004). An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28: 977-987. (Pubitemid 38971421)
19. Hruban RH, Wilentz RE, Kern SE. (2000). Genetic progression in the pancreatic ducts. Am J Pathol 156: 1821-1825. (Pubitemid 30641750)
20. Hunter T, Sefton BM. (1980). Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci USA 77: 1311-1315. (Pubitemid 10072278)
21. Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S et al. (2006). Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20: 3147-3160. (Pubitemid 44790629)
22. Irby RB, Yeatman TJ. (2000). Role of Src expression and activation in human cancer. Oncogene 19: 5636-5642.
23. Ishizawar R, Parsons SJ. (2004). c-Src and cooperating partners in human cancer. Cancer Cell 6: 209-214. (Pubitemid 39222033)
24. Izeradjene K, Combs C, Best M, Gopinathan A, Wagner A, Grady WM et al. (2007). Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 11: 229-243. (Pubitemid 46349845)
25. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R et al. (2001). Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15: 3243-3248. (Pubitemid 34008190)
26. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225-249.
27. Kabil A, Silva E, Kortenkamp A. (2008). Estrogens and genomic instability in human breast cancer cells-involvement of Src/Raf/ Erk signaling in micronucleus formation by estrogenic chemicals. Carcinogenesis 29: 1862-1868.
28. Kasahara K, Nakayama Y, Nakazato Y, Ikeda K, Kuga T, Yamaguchi N. (2007). Src signaling regulates completion of abscission in cytokinesis through ERK/MAPK activation at the midbody. J Biol Chem 282: 5327-5339. (Pubitemid 47093765)
29. Kline CL, Jackson R, Engelman R, Pledger WJ, Yeatman TJ, Irby RB. (2008). Src kinase induces tumor formation in the c-SRC C57BL/6 mouse. Int J Cancer 122: 2665-2673. (Pubitemid 351631367)
30. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. (2009). Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 101: 263-268.
31. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. (2004). Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hy-droxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47: 6658-6661. (Pubitemid 40053752)
32. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H et al. (1998). Overexpression and activation of the tyrosine kinase src in human pancreatic carcinoma. Biochem Biophys Res Commun 243: 503-508. (Pubitemid 28414054)
33. Maddalena AS, Hainfellner JA, Hegi ME, Glatzel M, Aguzzi A. (1999). No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice. Brain Pathol 9: 627-637. (Pubitemid 29470955)
34. Martin GS. (2001). The hunting of the src. Nat Rev Mol Cell Biol 2: 467-475.
35. Matsumoto T, Kiguchi K, Jiang J, Carbajal S, Ruffino L, Beltran L et al. (2004). Development of transgenic mice that inducibly express an active form of c-src in the epidermis. Mol Carcinog 40: 189-200. (Pubitemid 39056311)
36. Morton JP, Karim SA, Graham K, Timpson P, Jamieson N, Athineos D et al. (2010). Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma. Gastroenter-ology 139: 292-303.
37. Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K et al. (2008). Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 105: 9343-9348.
38. Podsypanina K, Politi K, Beverly LJ, Varmus HE. (2008). Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci USA 105: 5242-5247. (Pubitemid 351738541)
39. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD et al. (2009). Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 69: 1383-1391.
40. Rous P. (1911). A sarcoma of the fowl transmissable by an agent separable from the tumor cells. J Exp Med 13: 397-411.
41. Rucci N, Recchia I, Angelucci A, Alamanou M, Del Fattore A, Fortunati D et al. (2006). Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther 318: 161-172.
42. Schmedt C, Saijo K, Niidome T, Kuhn R, Aizawa S, Tarakhovsky A. (1998). Csk controls antigen receptor-mediated development and selection of T-lineage cells. Nature 394: 901-904. (Pubitemid 28410913)
43. Stehelin D, Varmus HE, Bishop JM, Vogt PK. (1976). DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260: 170-173.
44. Talamonti MS, Roh MS, Curley SA, Gallick GE. (1993). Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91: 53-60. (Pubitemid 23037252)
45. Thomas RM, Kim J, Revelo-Penafiel MP, Angel R, Dawson DW, Lowy AM. (2008). The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 57: 1555-1560.
46. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA et al. (2007). The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67: 6075-6082. (Pubitemid 47037486)
47. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY et al. (2006). Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarci-noma cells in an orthotopic nude mouse model. Am J Pathol 168: 962-972. (Pubitemid 43327748)
48. Vidal M, Larson DE, Cagan RL. (2006). Csk-deficient boundary cells are eliminated from normal Drosophila epithelia by exclusion, migration, and apoptosis. Dev Cell 10: 33-44. (Pubitemid 43025675)
49. Vitali R, Mancini C, Cesi V, Tanno B, Piscitelli M, Mancuso M et al. (2009). Activity of tyrosine kinase inhibitor Dasatinib in neuro-blastoma cells in vitro and in orthotopic mouse model. Int J Cancer 125: 2547-2555.
50. Warshaw AL, Fernandez-del Castillo C. (1992). Pancreatic carcinoma. N Engl J Med 326: 455-465.
51. Yezhelyev MV, Koehl G, Guba M, Brabletz T, Jauch KW, Ryan A et al. (2004). Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 10: 8028-8036. (Pubitemid 39587544)